Table 3 |
|||
|
OXTR promoter CpG methylation status in peripheral blood mononuclear cells (PBMCs) and cortex samples of males |
|||
|
Site |
AutD cases (95%CI), (n = 10) |
Controls (95%CI), (n = 10) |
t Test |
|
|
|||
|
PBMCs: |
|||
|
-860 |
41.0% (28.4 to 53.7) |
13.8% (6.6 to 21.0) |
0.0008 |
|
-901 |
48.1% (33.6 to 62.7) |
36.9% (19.1 to 54.7) |
0.3153 |
|
-924 |
71.1% (59.4 to 82.8) |
59.3% (40.8 to 77.8) |
0.2604 |
|
-934 |
58.7% (39.4 to 78.1) |
19.8% (3.2 to 36.4) |
0.0029 |
|
-959 |
48.6% (39.5 to 57.6) |
41.7% (27.5 to 55.9) |
0.3522 |
|
Cortex: |
|||
|
-860 |
38.8% (5.4 to 72.2) |
14.9% (3.6 to 26.2) |
0.1208 |
|
-901 |
47.1% (13.1 to 81.2) |
13.3% (3.6 to 23.0) |
0.0508 |
|
-924 |
64.3% (30.6 to 98.0) |
26.6% (7.2 to 46.1) |
0.0375 |
|
-934 |
61.0% (24.4 to 97.5) |
19.4% (1.1 to 37.7) |
0.0320 |
|
-959 |
20.5% (8.0 to 32.9) |
19.4% (1.1 to 37.7) |
0.9032 |
|
|
|||
|
Bold text indicates a significant result by Satterthwaite test; %, percentage methylated. Cases and controls were all male. CI = confidence interval; AutD = autism disorder. |
|||
|
Gregory et al. BMC Medicine 2009 7:62 doi:10.1186/1741-7015-7-62 |
|||
